"With 13 Commercially Available Products Globally and More than 200 in Clinical Trials, ADC Market is Set to Grow Exponentially" BOSTON , Oct. 21, 2024 /PRNewswire/ -- "According to the latest BCC Research study, "The global ADCs market is showing a rapid growth trend, with growth rates of 36.5% and 40.
7% in 2022 and 2023, respectively, reaching a value of $10.8 billion in 2023." The market is projected to grow to more than $47.
0 billion by the end of 2029." ADCs are at the forefront of precision medicine, offering high specificity for cancer cells while minimizing toxicity. With 13 commercially available products globally and more than 200 in clinical trials, ADC development has become one of the most attractive classes of biological drugs.
Significant investment in research and development by pharmaceutical and biotech companies and the increasing number of ADCs in clinical trials are important drivers of the ADC market. As per a BCC analyst, "The technical and regulatory success (PTRS) probability for ADCs is higher than that of the other oncology categories. The relatively high PTRS of ADCs helps explain both the frequency and magnitude of deals and investor confidence in the ADC space.
" Collaborations and licensing deals accounted for most of the deals in the space, followed by acquisition. Investors are attracted to companies that pioneer innovative payloads, conjugation technologies, or linkers. With leading pharmaceutical giants such as Pfizer, Johnson & Johnson, AbbV.
